Emerald Health, Skye Bioscience merger gets court approval in Canada
Emerald Health, Skye Bioscience merger gets court approval in Canada
115.88MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US83086J2006
CUSIP
83086J101
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
1.91
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.83
Wall Street Target Price
15.50
EPS Estimate Current Year
-1.14
EPS Estimate Next Year
-1.38
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.2825
Most Recent Quarter
-
Revenue TTM
0
Gross Profit TTM
0
EBITDA
-35,353,772
Profit Margin
0.00%
Return On Assets TTM
-28.04%
Return On Equity TTM
-47.27%
Revenue Per Share TTM
0
Qtly Revenue Growth YOY
0.00%
Diluted Eps TTM
-0.83
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0
Price Book MRQ
2.1807
Enterprise Value Revenue
0
Enterprise Value EBITDA
-2
333.19
1.11%79.37
0.80%549.48
0.33%244.89
0.29%457.57
0.14%547.60
0.08%98.27
0.02%151.02
0.00%199.89
0.00%540.97
-1.08%